Tenax Therapeutics Inc

NASDAQ:TENX   9:54:04 AM EDT
0.62
+0.04 (+6.86%)
Earnings Announcements

Tenax Sees Cash, Cash Equivalents, Marketable Securities To Be Enough To Fund Ops Through Q2

Published: 03/31/2022 12:46 GMT
Tenax Therapeutics Inc (TENX) - Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update.
Tenax Therapeutics - Expects Current Cash, Cash Equivalents and Marketable Securities Will Be Sufficient to Fund Current Operations Through Q2 2022.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.09

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.09

More details on our Analysts Page.